The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming
Autor: | Dehua Tang, Yida Pan, Lixing Zhou, Chengfei Jiang, Lei Xu, Robert G. Dorfman, Mingming Zhang, Yuyao Yin, Xiaoping Zou, Lei Wang, Jian-lin Wu, Yuming Wang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Male Cancer Research Original article Mice Nude Apoptosis Oxidative phosphorylation Biology medicine.disease_cause SIRT2 lcsh:RC254-282 Oxidative Phosphorylation Serine Cholangiocarcinoma Proto-Oncogene Proteins c-myc 03 medical and health sciences Mice 0302 clinical medicine Sirtuin 2 Cell Movement medicine Tumor Cells Cultured Animals Humans Pyruvate Dehydrogenase (Lipoamide) Cell Proliferation Regulation of gene expression Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cellular Reprogramming Prognosis Warburg effect Xenograft Model Antitumor Assays Mitochondria Gene Expression Regulation Neoplastic Oxidative Stress 030104 developmental biology Glucose Bile Duct Neoplasms 030220 oncology & carcinogenesis Cancer research Female Histone deacetylase Oxidative stress |
Zdroj: | Neoplasia (New York, N.Y.) Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 5, Pp 429-441 (2019) |
ISSN: | 1476-5586 1522-8002 |
Popis: | Cholangiocarcinoma (CCA) is a malignant cancer with an unknown etiology and an unfavorable prognosis. Most patients are diagnosed at an advanced stage, thus making it essential to find novel curative targets for CCA. Metabolic reprogramming of the tumor cells includes metabolic abnormalities in glucose (known as the Warburg effect) and other substances such as amino acids and fats. Metabolic reprogramming produces anti-oxidant substances, reduces tumor oxidative stress, and finally promotes the proliferation of tumors. There is increasing evidence to imply that SIRT2, a histone deacetylase, and its downstream target cMYC, play metabolic regulatory roles in tumor cells. However, the role of the SIRT2/cMYC pathway in CCA is unclear. To assess the metabolic reprogramming function of the SIRT2/cMYC pathway in CCA and to determine the downstream targets as well as evaluate the therapeutic effect, the CCA RNA-Seq data were downloaded from the TCGA database. Differentially expressed genes were confirmed and KEGG pathway enrichment analysis was performed. Overall, 48 paired CCA samples were collected and subjected to immunohistochemical detection, and the clinical characteristics of participants were summarized. The CCA cells were suppressed or overexpressed with different downstream targets of SIRT2 and then subjected to apoptosis, immunoblotting, seahorse, and metabolites tracing analysis. In vivo experiments were also performed. We found that the SIRT2/cMYC pathway contributed to the proliferation of CCA cells and confirmed that the downstream target is PHDA1 and the serine synthesis pathway. The up-regulated SIRT2 and cMYC levels resulted in low levels of mitochondrial oxidative phosphorylation and increased conversion of glucose to serine and led to poor patient survival. The highly active SIRT2/cMYC pathway up-regulated the serine synthesis pathway pyruvate and increased antioxidant production, thus consequently protecting the CCA cells from oxidative stress-induced apoptosis. Our data revealed that the SIRT2/cMYC pathway plays a critical role in transforming glucose oxidative metabolism to serine anabolic metabolism, thus providing antioxidants for stress resistance. SIRT2/cMYC-induced metabolic reprogramming may represent a new therapeutic target for treating CCA. |
Databáze: | OpenAIRE |
Externí odkaz: |